Welcome to a new episode of our Benzinga Psychedelics Podcast. We are joined herein by executives of Clearmind Medicine (NASDAQ:CMND), a biotech company developing a proprietary, psychoactive yet non-hallucinogenic treatment for a diverse array of addictive behaviors, with Alcohol Use Disorder (aka AUD) as its first indication pursued.

In conversation with guests Dr. Adi Zuloff-Shani, Cleamind's CEO, and Mark Haden, VP of business development and an addiction counseling and management specialist, we dive into the world of addiction treatment and what the intriguing molecule known as MEAI can do in different behavioral scenarios, including binge eating...